{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-277601","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.926981+00:00","generated_at":"2026-05-16T21:37:22.077281+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BBOT Q3 2025 net loss $44.8M; cash $468.3M funds operations into 2028","bullets":["Net loss of $44.8M vs $17.3M in Q3 2024; R&D expenses $35.1M, G&A $14.1M.","Cash, equivalents and marketable securities $468.3M; runway expected into 2028.","Closed SPAC business combination with Helix Acquisition Corp II on Aug 11, 2025; began trading on Nasdaq as BBOT.","Appointed Uneek Mehra as CFO in July 2025.","Three Phase 1 trials advancing (BBO-8520, BBO-10203, BBO-11818); initial clinical data readouts expected in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-277601","json":"https://secwatch.observer/filing/0001193125-25-277601.json","markdown":"https://secwatch.observer/filing/0001193125-25-277601.md","text":"https://secwatch.observer/filing/0001193125-25-277601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000119312525277601/0001193125-25-277601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000119312525277601/d814249d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:37:22.077281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}